

(19)



(11)

EP 2 298 811 B8

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
A61K 39/395^(2006.01) C07K 16/24^(2006.01)

(48) Corrigendum issued on:
18.02.2015 Bulletin 2015/08

(45) Date of publication and mention
of the grant of the patent:
26.11.2014 Bulletin 2014/48

(21) Application number: **10075518.0**

(22) Date of filing: **16.10.2003**

(54) **Human anti-IFN-gamma neutralizing antibodies as selective IFN-gamma pathway inhibitors**

Menschliche Anti-IFN-Gamma-neutralisierende Antikörper als selektive IFN-Gamma-Pfadhemmer
Anticorps humains à neutralisation anti-IFN-gamma en tant qu'inhibiteurs sélectifs de chemin IFN-gamma

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PT RO SE SI SK TR**
Designated Extension States:
AL LT LV MK

- Chute, Hilary, T
Calabasas, CA 91302 (US)
- Li Yue-Sheng
Thousand Oaks, CA 91360 (US)
- Huang, Haichun
Fremont, CA 94538-5919 (US)

(30) Priority: **16.10.2002 US 419057**
17.06.2003 US 479241

(74) Representative: **Grünecker, Kinkeldey,
Stockmair & Schwanhäusser
Leopoldstrasse 4
80802 München (DE)**

(43) Date of publication of application:
23.03.2011 Bulletin 2011/12

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
03777635.8 / 1 578 936

(56) References cited:
WO-A2-99/09055 US-B1- 6 329 511

- (73) Proprietors:
- **Amgen Inc.**
Thousand Oaks, CA 91320-1799 (US)
 - **E. R. Squibb & Sons, L.L.C.**
Princeton, NJ 08540 (US)

- **LANDOLFI N F ET AL: "The integrity of the ball-and-socket joint between V and C domains is essential for complete activity of a humanized antibody", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 166, no. 3, 1 February 2001 (2001-02-01), pages 1748-1754, XP002959847, ISSN: 0022-1767**

- (72) Inventors:
- **Welcher, Andrew A**
Ventura, CA 93001 (US)

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 298 811 B8

- **FIorentini S et al: "A partially humanized monoclonal antibody to human IFN-gamma inhibits cytokine effects both in vitro and in vivo", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, BLACKWELL SCIENCE PUBL., OXFORD, GB, vol. 55, no. 3, March 2002 (2002-03), pages 284-292, XP002347393, ISSN: 0300-9475**

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification